Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Talimogene laherparepvec by Amgen for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Talimogene laherparepvec by Amgen for Kaposi Sarcoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Kaposi Sarcoma. According to GlobalData, Phase...
Talimogene laherparepvec by Amgen for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...
Talimogene laherparepvec by Amgen for Metastatic Colorectal Cancer: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Talimogene laherparepvec by Amgen for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Talimogene laherparepvec by Amgen for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
Talimogene laherparepvec by Amgen for Non-Small Cell Lung Cancer: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Talimogene laherparepvec by Amgen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Talimogene laherparepvec by Amgen for Solid Tumor: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Talimogene laherparepvec by Amgen for Merkel Cell Carcinoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...
Talimogene laherparepvec by Amgen for Soft Tissue Sarcoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...
Talimogene laherparepvec by Amgen for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...
Talimogene laherparepvec by Amgen for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Talimogene laherparepvec by Amgen for Kaposi Sarcoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Kaposi Sarcoma. According to GlobalData, Phase...
Talimogene laherparepvec by Amgen for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...
Talimogene laherparepvec by Amgen for Metastatic Colorectal Cancer: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Talimogene laherparepvec by Amgen for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Talimogene laherparepvec by Amgen for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
Talimogene laherparepvec by Amgen for Non-Small Cell Lung Cancer: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Talimogene laherparepvec by Amgen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...